In the paper we further refine the thermodynamics method of black hole/CFT correspondence. We show that one can derive the central charges of different holographic pictures directly from the entropy product S+S− if it is mass-independent, for a black hole in the Einstein gravity or the gravity without diffeomorphism anomaly. For a general black hole in the Einstein gravity that admits holographic descriptions, we show that the thermodynamics method and asymptotic symmetry group (ASG) analysis can always give consistent results in the extreme limit. Furthermore, we discuss the relation between black hole thermodynamics and the hidden conformal symmetry. We show that the condition T+A+ = T−A−, with A± being the outer and inner horizon areas, is the necessary, but not sufficient, condition for a black hole to have the hidden conformal symmetry. In particular, for the Einstein(-Maxwell) gravity T+A+ = T−A− is just the condition T+S+ = T−S−, with S± being the outer and inner horizon entropies, which is the condition for the entropy product S+S− being mass-dependent. When there exists the hidden conformal symmetry in the low-frequency scattering off the generic non-extremal black hole, it always leads to the same temperatures of dual CFT as the ones got from the thermodynamics method. *

LNR was associated with a significantly poorer OS and LNR was an independent predictor of survival in patients with gastric cancer. LNR should be added as one of the parameters to be used in future tumor staging classification systems.

Background Although the benefits of sodium–glucose cotransporter 2 inhibitors (SGLT2i) on cardiovascular events have been reported in patients with type 2 diabetes mellitus (T2DM) with or without heart failure (HF), the impact of SGLT2i on cardiac remodelling remains to be established. Methods We searched the PubMed, Embase, Cochrane Library and Web of Science databases up to November 16th, 2020, for randomized controlled trials reporting the effects of SGLT2i on parameters of cardiac structure, cardiac function, plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) level or the Kansas City Cardiomyopathy Questionnaire (KCCQ) score in T2DM patients with or without chronic HF. The effect size was expressed as the mean difference (MD) or standardized mean difference (SMD) and its 95% confidence interval (CI). Subgroup analyses were performed based on the stage A–B or stage C HF population and HF types. Results Compared to placebo or other antidiabetic drugs, SGLT2i showed no significant effects on left ventricular mass index, left ventricular end diastolic volume index, left ventricular end systolic volume index, or left atrial volume index. SGLT2i improved left ventricular ejection fraction only in the subgroup of HF patients with reduced ejection fraction (MD 3.16%, 95% CI 0.11 to 6.22, p = 0.04; I2 = 0%), and did not affect the global longitudinal strain in the overall analysis including stage A–B HF patients. SGLT2i showed benefits in the E/e’ ratio (MD − 0.45, 95% CI − 0.88 to − 0.03, p = 0.04; I2 = 0%), plasma NT-proBNP level (SMD − 0.09, 95% CI − 0.16 to − 0.03, p = 0.004; I2 = 0%), and the KCCQ score (SMD 3.12, 95% CI 0.76 to 5.47, p  = 0.01; I2 = 0%) in the overall population. Conclusion The use of SGLT2i was associated with significant improvements in cardiac diastolic function, plasma NT-proBNP level, and the KCCQ score in T2DM patients with or without chronic HF, but did not significantly affect cardiac structural parameters indexed by body surface area. The LVEF level was improved only in HF patients with reduced ejection fraction.

No abstract